Literature DB >> 8427379

Inhibitory effects of sinefungin and its cyclic analog on the multiplication of Trypanosoma cruzi isolates.

J L Avila1, A Avila, M A Polegre.   

Abstract

Sinefungin and its cyclic analog were evaluated in vitro for activity against the multiplication of Trypanosoma cruzi. When either drug was tested for eight days on twelve T. cruzi epimastigote isolates, an 800-fold difference in drug sensitivity was found. Both drugs were trypanostatics at a concentration range from 0.1 micrograms/ml to 300 micrograms/ml. The 50% effective concentration (EC50) of sinefungin and its cyclic analog at which the growth of a given isolate was inhibited was 0.38 micrograms/ml for sinefungin and 0.31 micrograms/ml for the cyclic analog against the Ma, Marin, OPS-86, Y, and Ya isolates, and > 300 micrograms/ml for sinefungin and 217 micrograms/ml for the cyclic analog against the A-35, Bertoldo, DS, EP, ES, OPS-58, and FL isolates. Incubation of drug-sensitive isolates for more than 10 days in glucose-saline (GS) medium, but not in minimal essential medium, in the presence of a 30-fold EC50 concentration of the drug induced an increase in the drug-resistant population, which maintained this phenotype for several passages in drug-free culture medium. Growth curves were analyzed as a function of parasite inoculum; it was observed that with sinefungin-sensitive T. cruzi epimastigote isolates grown in GS medium in the presence of 10 micrograms/ml of the drug, the inhibitory effects of the drug were dependent on the initial inoculum: 1 x 10(3)-1 x 10(4) parasites/ml were strongly inhibited even after 16 days. Significant impairment of thymidine incorporation into the DNA of parasites by both drugs was observed only in drug-sensitive epimastigote isolates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8427379     DOI: 10.4269/ajtmh.1993.48.112

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  2 in total

1.  Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology.

Authors:  Zheng Zhao; Che Martin; Raymond Fan; Philip E Bourne; Lei Xie
Journal:  BMC Bioinformatics       Date:  2016-02-18       Impact factor: 3.169

2.  Characterization of the RNA-Binding Protein TcSgn1 in Trypanosoma cruzi.

Authors:  Camila Oliveira; André P Gerber; Samuel Goldenberg; Lysangela R Alves
Journal:  Microorganisms       Date:  2021-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.